These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 10720524)

  • 81. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough.
    Giammanco A; Taormina S; Chiarini A; Dardanoni G; Stefanelli P; Salmaso S; Mastrantonio P
    Vaccine; 2003 May; 21(17-18):1924-31. PubMed ID: 12706678
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Are only antibody levels involved in the protection against pertussis in acellular pertussis vaccine recipients?
    Cassone A; Mastrantonio P; Ausiello CM
    J Infect Dis; 2000 Nov; 182(5):1575-7. PubMed ID: 11023488
    [No Abstract]   [Full Text] [Related]  

  • 84. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
    Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
    Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
    Podda A; De Luca EC; Titone L; Casadei AM; Cascio A; Peppoloni S; Volpini G; Marsili I; Nencioni L; Rappuoli R
    J Pediatr; 1992 May; 120(5):680-5. PubMed ID: 1578301
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.
    Nascimento IP; Dias WO; Mazzantini RP; Miyaji EN; Gamberini M; Quintilio W; Gebara VC; Cardoso DF; Ho PL; Raw I; Winter N; Gicquel B; Rappuoli R; Leite LC
    Infect Immun; 2000 Sep; 68(9):4877-83. PubMed ID: 10948100
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Antibody levels against B. pertussis in neonates measured in dried blood spots.
    van Ommen CC; Elvers LH; Notermans DW; van Huisseling JC; Teunis PF; Versteegh FG
    Vaccine; 2012 Mar; 30(16):2697-700. PubMed ID: 22227147
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A ten year follow-up after immunization with a two component acellular pertussis vaccine.
    Tindberg Y; Blennow M; Granström M
    Pediatr Infect Dis J; 1999 Apr; 18(4):361-5. PubMed ID: 10223691
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine.
    Robbins JB; Pittman M; Trollfors B; Lagergard TA; Taranger J; Schneerson R
    Pediatr Infect Dis J; 1993 Oct; 12(10):795-807. PubMed ID: 8284114
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical trials of acellular pertussis vaccine in Sweden. An attempt to solve the problem of pertussis vaccination.
    Olin P
    Ann Sclavo Collana Monogr; 1986; 3(1-2):165-72. PubMed ID: 2892504
    [No Abstract]   [Full Text] [Related]  

  • 91. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis.
    Versteegh FG; Mertens PL; de Melker HE; Roord JJ; Schellekens JF; Teunis PF
    Epidemiol Infect; 2005 Aug; 133(4):737-48. PubMed ID: 16050521
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Concentrations of Immunoglobulin G Antibodies Against Pertussis Toxin Does Not Decrease Over a Long Period of Time in Japan.
    Sakakibara Y; Ohtani Y; Jinta T; Fujie T; Miyazaki Y; Inase N; Saito R; Akaza M; Sasano T; Sumi Y
    Intern Med; 2016; 55(22):3257-3263. PubMed ID: 27853066
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Contents of antibodies to Bordetella pertussis antigens in patients with rheumatic diseases].
    Kostinov MP; Tarasova AA; Zaĭtsev EM
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (6):61-4. PubMed ID: 18277540
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old children.
    Krantz I; Sekura R; Trollfors B; Taranger J; Zackrisson G; Lagergård T; Schneerson R; Robbins J
    J Pediatr; 1990 Apr; 116(4):539-43. PubMed ID: 2319400
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pertussis antibodies, protection, and vaccine efficacy after household exposure.
    Storsaeter J; Blackwelder WC; Hallander HO
    Am J Dis Child; 1992 Feb; 146(2):167-72. PubMed ID: 1733145
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pertussis whole cell vaccine: relation between intracerebral protection in mice and antibody response to pertussis toxin, filamentous hemagglutinin and adenylate cyclase.
    Dellepiane NI; Manghi MA; Eriksson PV; di Paola G; Cangelosi A
    Zentralbl Bakteriol; 1992 Jun; 277(1):65-73. PubMed ID: 1520970
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Immunization status of Iranian military recruits against Bordetella pertussis infection (whooping cough).
    Izadi M; Afsharpaiman S; Jonaidi Jafari N; Ranjbar R; Gooya MM; Robat Sarpooshi J; Esfahani AA; Soheylipoor H
    J Infect Dev Ctries; 2011 Mar; 5(3):224-6. PubMed ID: 21444992
    [TBL] [Abstract][Full Text] [Related]  

  • 98. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.
    Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R
    Vaccine; 2014 Jun; 32(27):3350-6. PubMed ID: 24793938
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines.
    Odelram H; Granström M; Hedenskog S; Duchén K; Björkstén B
    Pediatr Allergy Immunol; 1994 May; 5(2):118-23. PubMed ID: 8087191
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Monoclonal antibody against pertussis toxin: relationship between toxin neutralization and mouse protection activities.
    Sato H; Sato Y; Ito A
    Ann Sclavo Collana Monogr; 1986; 3(1-2):259-67. PubMed ID: 2962594
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.